http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-9809330-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94ff2d78578d95d1e8d3a2233c76188d
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-14
filingDate 1998-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_082a0d999a5b004686a6446e4472f313
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ea6c3d80798e1aa582c73fc823c2832
publicationDate 2000-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber BR-9809330-A
titleOfInvention Halotherapy development process
abstract Invention Patent: <B> "HALOTHERAPY DEVELOPMENT PROCESS" <D>. Process for providing halotherapy to the upper part (22-26) of the lower respiratory tract (20), which includes the steps of operating a dispenser (30) and inhalation. The dispenser (30) contains a dry sodium chloride powder. The user operates the dispenser (30) to release a dosage of powder for inhalation when the dispenser (30) is directed to the user's mouth. The user then inhales the powder dosage through the mouth. Due to the fact that the powder has a particle size range that allows the powder to reach the upper part (22-26) of the lower respiratory tract (20) without being introduced into the user's lungs, the dry powder dosage presents a concentration at the top (22-26) enough to provide effective halotherapy. The preferred particle size is about 5 microns to about 20 microns. The preferred dosage is about 3 milligrams of powder.
priorityDate 1997-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448670727
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5234

Total number of triples: 14.